Compare PRCT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCT | IVA |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | PRCT | IVA |
|---|---|---|
| Price | $25.87 | $5.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $35.44 | $16.20 |
| AVG Volume (30 Days) | ★ 1.5M | 230.0K |
| Earning Date | 04-29-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $308,054,000.00 | N/A |
| Revenue This Year | $31.34 | N/A |
| Revenue Next Year | $24.52 | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $19.35 | $2.94 |
| 52 Week High | $64.89 | $7.98 |
| Indicator | PRCT | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 39.77 |
| Support Level | $22.05 | $4.98 |
| Resistance Level | $26.41 | $6.42 |
| Average True Range (ATR) | 1.90 | 0.25 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 60.10 | 12.18 |
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.